Impact of the diagnostic label for a low-risk prostate lesion: protocol for two online factorial randomised experiments.
James BullenBrooke NickelKirsten Jo McCafferyTimothy J WiltJenna SmithFarzaneh BoroumandLisa ParkerJeremy L MillarJohn Brandt BrodersenPhilipp DahmBrett DelahuntMurali VarmaPaul P GlasziouAndrew WardenLawrence DillerLarry BillingtonChristo van RensburgKaty J L BellPublished in: BMJ open (2024)
Ethics approval has been received from The University of Sydney Human Research Ethics Committee (2023/572). The results of the study will be published in a peer-reviewed medical journal and a plain language summary of the findings will be shared on the Wiser Healthcare publications page http://www.wiserhealthcare.org.au/category/publications/ TRIAL REGISTRATION NUMBERS: Australian New Zealand Clinical Trials Registry (ID 386701 and 386889).
Keyphrases
- clinical trial
- healthcare
- public health
- phase ii
- study protocol
- prostate cancer
- endothelial cells
- open label
- big data
- randomized controlled trial
- health information
- double blind
- autism spectrum disorder
- social media
- induced pluripotent stem cells
- pluripotent stem cells
- benign prostatic hyperplasia
- machine learning
- reduced graphene oxide
- meta analyses